Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 8/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCND3 | P30281 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 7/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5034282 | 0.90 | CAPN1 (0.42) | SCN9APIN1 | |
| SCHEMBL6427150 | 0.87 | SCN9A (0.43) | SCN9ACHEK1CDK1CDK4CCNA2 | |
| SCHEMBL5029958 | 0.86 | TRPV3 (0.45) | SCN9ACHEK1CDK1CDK4CCNA2 | |
| SCHEMBL5034336 | 0.85 | ROCK1 (0.43) | CHEK1CDK1CDK4CCNA2CCND1 | |
| SCHEMBL5031128 | 0.82 | SCN9A (0.48) | SCN9ACNR2CNR1ROCK2ROCK1 | |
| SCHEMBL4148339 | 0.80 | CHEK1 (0.47) | CHEK1CDK1CDK4CCNA2CCND1 | |
| SCHEMBL4148344 | 0.80 | CHEK1 (0.47) | CHEK1CDK1CDK4CCNA2CCND1 | |
| SCHEMBL5030106 | 0.79 | CHEK1 (0.40) | CHEK1CDK1CDK4CCNA2CCND1 | |
| SCHEMBL4146553 | 0.79 | DYRK1A (0.43) | CHEK1CDK1CDK4CCNA2CCND1 | |
| SCHEMBL4146547 | 0.79 | DYRK1A (0.43) | CHEK1CDK1CDK4CCNA2CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-7429609-B2 | Pyrazole compound and medicinal composition containing the same | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | SCN9A 2678/4885CHEK1 657/4885CDK1 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.